We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

115 hedge funds and large institutions have $2.76B invested in Infinity Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $1.38M

77% more capital invested

Capital invested by funds: $1.56B → $2.76B (+$1.2B)

11% less funds holding

Funds holding: 129115 (-14)

17% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 41

47% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 30

Holders
115
Holders Change
-14
Holders Change %
-10.85%
% of All Funds
3.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
34
Reduced
41
Closed
30
Calls
$3.19M
Puts
$1.38M
Net Calls
+$1.81M
Net Calls Change
-$681K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
Americafirst Capital Management
California
$2.38B +$1.47M +170,307 +129%
Vanguard Group
2
Vanguard Group
Pennsylvania
$48.9M +$5.33M +618,924 +11%
O
3
OrbiMed
New York
$34.7M
DM
4
Deerfield Management
New York
$33.8M +$3.4M +394,567 +10%
Goldman Sachs
5
Goldman Sachs
New York
$23M -$21.2M -2,462,774 -46%
BFA
6
BlackRock Fund Advisors
California
$21.6M -$408K -47,431 -2%
BB
7
BB Biotech
Switzerland
$21.2M
Fidelity Investments
8
Fidelity Investments
Massachusetts
$18.5M +$2.21M +256,800 +12%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$16.8M -$2.48M -288,454 -12%
State Street
10
State Street
Massachusetts
$16.4M -$14.1M -1,641,479 -44%
Millennium Management
11
Millennium Management
New York
$11.4M +$11M +1,274,197 +700%
PA
12
Pinnacle Associates
New York
$11.4M +$930K +108,051 +8%
BIT
13
BlackRock Institutional Trust
California
$10.8M -$14K -1,629 -0.1%
NI
14
Numeric Investors
Massachusetts
$9.34M +$8.69M +1,008,867 +557%
OAM
15
Oxford Asset Management
United Kingdom
$7.55M +$8.18M +949,935 +7,496%
Ameriprise
16
Ameriprise
Minnesota
$5.41M +$3.1M +360,464 +110%
TA
17
Teachers Advisors
New York
$5.05M +$692K +80,360 +14%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$4.82M -$253K -29,400 -5%
Northern Trust
19
Northern Trust
Illinois
$4.67M +$131K +15,213 +3%
BA
20
BlackRock Advisors
Delaware
$4.61M -$281K -32,696 -5%
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$4.6M +$902K +104,775 +22%
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$4.57M -$3.87M -449,616 -44%
JP Morgan Chase
23
JP Morgan Chase
New York
$3.93M -$612K -71,050 -12%
Norges Bank
24
Norges Bank
Norway
$3.93M
Deutsche Bank
25
Deutsche Bank
Germany
$3.6M +$549K +63,788 +16%

INFI Hedge Fund Activity: Q4 2015 in Review

115 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2015, worth a combined $2.76B — up 77% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of INFI and 16 opened new positions — a net loss of 14 holders — while 41 trimmed existing stakes and 34 added.

The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was Goldman Sachs, cutting an estimated $21.2M.

  • 115 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2015, down from 129 in Q3 2015.
  • Funds reported $2.76B of Infinity Pharmaceuticals, Inc. stock for Q4 2015, up 77% quarter-over-quarter.
  • 16 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2015 and 30 closed out, a net change of -14 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2015 was Millennium Management, an estimated $11M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q4 2015 was Goldman Sachs, an estimated $21.2M sold.

Based on aggregated 13F filings for Q4 2015.